Daniel Hochhauser

机构：Royal London Hospital, London Cancer, University College London · ORCID：0000-0001-5522-9281

发表论文 353 篇 · 总被引 12629 次 · h-index 51

代表论文

• Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer (2025 · New England Journal of Medicine · 被引 96)
• Trellis tree-based analysis reveals stromal regulation of patient-derived organoid drug responses (2023 · Cell · 被引 68)
• Homopolymer switches mediate adaptive mutability in mismatch repair-deficient colorectal cancer (2024 · Nature Genetics · 被引 20)
• Copy number architectures define treatment-mediated selection of lethal prostate cancer clones (2023 · Nature Communications · 被引 12)
• Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study. (2025 · Journal of Clinical Oncology · 被引 10)
• A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCL (2023 · Blood · 被引 9)